CellAct Pharma

Release Summary

Cellact's CAP7.1 has shown safety and initial efficacy in Phase I studies. Data were presented at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.

CellAct Pharma